8-K:臨時報告書
10-Q:四半期報告書
8-K:Revivaが2024年第1四半期の決算と最近の業績ハイライトを報告します
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:臨時報告書
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 10-K:有価証券報告書
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:臨時報告書
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:臨時報告書
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | NT 10-K:その他
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13D/A:大量保有報告書(訂正)-Laxminarayan Bhat(10.2%)
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13G/A:大量保有報告書(訂正)-TANG CAPITAL PARTNERS, LP(9.99%),TANG CAPITAL MANAGEMENT, LLC(9.99%)など
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13G:大量保有報告書-Armistice Capital, LLC(6.32%),Steven Boyd(6.32%)
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | EFFECT:その他
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 424B4:目論見書
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | CORRESP:文通
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | UPLOAD:その他
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | S-3:特定取引登録声明
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | SC 13D/A:大量保有報告書(訂正)-Parag Saxena(19.9%),Vedanta Partners, LLC(19.4%)など
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 4:インサイダー売買報告書-取締役 SAXENA PARAG
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 8-K:臨時報告書
REVIVA PHARMACEUTICALS HOLDINGS INC C/WTS 25/12/2025(TO PUR COM) | 424B5:目論見書
データなし